Allarity Therapeutics (ALLR) names Jesper Høiland to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Allarity Therapeutics Announces Changes to Board of Directors
June 11, 2025 4:05 PM EDTÂ Â Â
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenopariba differentiated, dual PARP and WNT pathway inhibitoras a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technologytoday announced that Jesper Høiland has been appointed to join the Companys Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allaritys development over the past two... More
